Mai Gene a Lead Clone: He aha ka Lonza's GS-ORI-GO Vectors Signal no ka Peptide Development Workflow

Pane wikiwiki

Lonza’s GS Ori-Go announcement concerns mammalian expression and cell-line development. It can motivate a discussion of connected workflows, but it does not es…

He aha nā mea GS-ORI-GO a Lonza e hoʻololi maoli ai i ka gene-to-lead-clone timeline

a ma mua/ma hope o ke kahe ʻana o ke kaʻina hoʻomohala cell-line, me ke kahe hana GS mua e hōʻike ana i ka hoʻololi, nui

Ua hōʻike ʻia ʻo Lonza i nā kiʻi platform GS Ori-Go Hōʻike ʻo Lonza i nā titers lead-clone ma luna 11 g/L a me ka paʻa wai nui a hiki i 97 pākēneka. Ua hōʻike ʻia ʻo Lonza i nā kiʻi platform GS Ori-Go. ʻikepili pae pae: Titer kēpau-clone (g/L) 11; Paʻa wai nui (%) 97; Paʻa Clone (%) 90.Puna: ʻōnaehana hōʻike Lonza GS . Ua hōʻike ʻia ʻo Lonza i nā kiʻi platform GS Ori-Go Titer kēpau-clone(g/L) 11 ʻauʻau nuikūpaʻa (%) 97 Paʻa Clone(%) 90 Puna: ʻōnaehana hōʻike Lonza GS

Mea Ho'āʻo Peptide Huina Polypeptide ʻO ka hoʻololi he hoʻoponopono kaʻina hana, ʻaʻole kahi laina kelepona hou. Ua wehewehe ʻo Lonza i ka GS-ORI-GO ma ke ʻano he hoʻololi o ka GS Xceed workflow e hoʻohui i kahi mea hoʻolaha huahana-hōʻike ikaika kiʻekiʻe a me ka mana ʻoi aku ka ikaika o ka glutamine synthetase. (ʻO ka ʻaoʻao pepa keʻokeʻo GS-ORI-GO o Lonza, 2026-10-08). Noho like ka hale hoʻokipa; he aha nā neʻe kahi e hoʻohana ʻia ai ke kaomi koho.

ʻO ka poʻomanaʻo ka holomua pololei mai nā loko nui a i nā laina cell clonal, ka wehe ʻana i ka pono o nā loko waiwai a me ka methionine sulfoximine (MSX) koho, per ʻO Lonza 3 Iune 2026 aʻoaʻo media. ʻO ka mīkini ma hope o kēlā stringency he structural: Loaʻa ʻole nā ​​​​pūnaewele CHOK1SV GS-KO i ka endogenous glutamine synthetase, no laila, ola wale nā ​​​​pūnaewele hoʻohui i ka vector i loko o ka media glutamine-free (ʻO ka nānā ʻana o ka ʻōnaehana hōʻike GS o Lonza).

Mai Gene a Lead Clone: He aha kā Lonza GS-ORI-GO Vectors hōʻailona no ka Peptide Development Workflow

Hōʻike ʻo Lonza i nā titers lead-clone kiʻekiʻe ma mua o 11 g/L a ʻoi aku ma mua o a 30% hoʻonui i nā titers ma nā mAbs, bispecifics a me fusion proteins (ʻO Lonza 3 Iune 2026 aʻoaʻo media), ma ka aoao 97% bulk pool paʻa me ka oi aku mamua o 90% paʻa clone (ʻO ka moʻolelo a Lonza no ka mālama ʻana i ka pae). Loaʻa kēlā mau helu i kahi hōʻailona kūpono e haʻi maʻalahi: ʻO kahi loiloi ʻoihana e hōʻailona ana i kekahi o Lonza i hōʻike ʻia i ka pool-stability a me ke alakaʻi-clone ʻikepili "ʻaʻole i hōʻike ʻia" (ʻoihana loiloi o nā ʻōnaehana koho CHO, 2026-07-26). Ua like ka palena o ke koi laina manawa. Hōʻike ʻo Lonza i ka lāʻau lāʻau toxicological-grade i loko o ʻelua mahina a me ka mākaukau IND i loko o ʻeono mahina., me ka footnote e hoʻokumu ʻia kēia ma luna o nā mea loko, mai ka hoʻololi ʻana i ka DNA a hiki i ka hāʻawi ʻana i nā modula CMC hiki i ka IND, nā manawa maʻamau, pili i ka ʻaelike me nā mana hoʻoponopono (ʻO Lonza ma ka hoʻolālā vector hōʻike mua, 2026-09-21).

ʻO kahi ʻāpana o ka wikiwiki ka hiʻohiʻona platform a ʻo ia ke kumu hoʻohui maʻamau

E hoʻokaʻawale i ka mīkini ponoʻī mai ka logic workflow a ʻike ʻia ka ʻāpana hoʻololi. ʻO ka mea Ori, ʻO ka mea hoʻolaha LHP-1 a me ka mīkini koho GS-KO he Lonza-specific a ʻaʻole e hoʻololi i kahi papahana peptide. He aha nā hoʻololi i ke kuhikuhi o ka hoʻoponopono: ua hoʻoneʻe ʻia kahi kaohi i hoʻoholo ʻia i lalo, a ua wehe ʻia kahi lima ma mua o ka wikiwiki.

Mai Gene a Lead Clone: He aha kā Lonza GS-ORI-GO Vectors hōʻailona no ka Peptide Development Workflow

Hōʻike ka mālama ʻana i ka ʻokoʻa. Hōʻike ʻo Lonza i ka wehe ʻana i ka hoʻonui ʻana a me ka koho MSX e mālama i ʻelua pule i ka hoʻomohala ʻana i nā laina kelepona, ma kahi o a 15% hōʻemi i nā gene-to-research cell bank timelines (ʻO ka moʻolelo a Lonza no ka mālama ʻana i ka pae). He hiʻohiʻona kēlā. ʻO ka loina ma lalo o ia mea, ʻelua mau papa koho i hāʻule i hoʻokahi, ʻo ia ka hoʻoholo hoʻolālā e hiki i kēlā me kēia hui hoʻomohala ke hana.

Hoʻokumu ka hōʻike bioprocess kūʻokoʻa i ke ʻano like me ka ʻole o ka inoa ʻana i kahi kahua: Hoʻonohonoho ka biology cell-line-development i ka hiki o ka manawa, ʻike pinepine ʻo analytics i ka wikiwiki o ka hoʻoholo ʻana i ka pale, a ʻo ka hoʻonohonoho ʻana a me ka hoʻololi ʻenehana e hoʻonui i nā mea ʻelua (hōʻike bioprocess ma kahi e kū ai nā hoʻoholo, 2026-07-26). Hōʻike nā ʻāpana hope o kahi mea kūʻai aku i ka convergence like mai kahi hoʻomaka ʻokoʻa: Hōʻike ʻo Sartorius i ka DNA e noiʻi i ka waihona kelepona ma ka wale nō 9 nā pule a me kahi panakō kelepona haku i hoʻokuʻu ʻia ma lalo o ʻelima mau mahina (Sartorius 4Cell platform brochure (PDF)). ʻOkoʻa nā helu hope a ʻaʻole hoʻohālikelike pololei, akā, hoʻopaʻa ʻelua i ka hopena mua a waiho i ka hoʻoholo analytical ma ke ʻano he puka.

He aha ka hoʻolālā kaʻina peptide mua e pono e loiloi ma mua o ka noi synthesis mua

kahi kaʻina peptide pōkole i hōʻike ʻia me nā hiʻohiʻona kikoʻī e wānana i ka paʻakikī synthesis - kahi kiko hydrophobic, a

ʻO ka hoʻolālā kaʻina peptide mua kahi i hoʻonohonoho ʻia ai ke kumukūʻai o lalo, no ka mea, hoʻoholo ke kaʻina i ka paʻakikī o ka synthesis a me ka hoʻomaʻemaʻe. ʻO kahi loiloi loiloi o ka hydrophobic peptide synthesis e ʻike i nā wānana: pūʻulu hydrophobic, beta-pepa a me ka aggregation propensity, haʻahaʻa haʻahaʻa uku hoʻoili, i ālai 'ia i ka hui 'ana ma Val, Me, Thr a me Pro, a me nā cysteine ​​he nui e hōʻemi ana i ka hua kaʻawale (ʻO ka nānā ʻana o nā hoa o ka hydrophobic peptide synthesis, 2020-03-04). He mau waiwai pae kaʻina, a ʻike ʻia lākou ma mua o ke kauoha ʻana i ka resin.

ʻO ka loiloi like nā palapala i ke kumu kūʻai paʻakikī. Ua pau nā peptide 50 i 60 He mea paʻakikī nā amino acids, a hāʻawi ʻia kahi ʻāpana hoʻokipa ʻiole bradykinin hydrophobic transmembrane 34 koena 4% hua i DMF a 12% i loko 80% NMP/DMSO (nānā ʻia e nā hoa Oxytocin Peptide ka loiloi o ka hydrophobic peptide synthesis). ʻO kahi ʻāpana 34-koena ʻaʻole ia he peptide lōʻihi, ʻo ia ke kiko: ʻO ka lōʻihi ka mea koho maikaʻi ʻole no ka paʻakikī.

ʻO ka pane kūpono he hoʻoholo hoʻolālā e pili ana i ka pale kuamoʻo. ʻO ka hoʻokomo ʻana i ka pale iwi kuamoʻo ma mua o ka hoʻomaka ʻana o ka hōʻuluʻulu ʻana a ma hope i kēlā me kēia ʻeono koena e pale i ka hoʻomaka ʻana o nā kaʻina paʻakikī. (holomua i ka Fmoc solid-phase peptide synthesis, 2016). He koho hoʻolālā synthesis kēlā, a ʻoi aku ka liʻiliʻi o ka hana ʻana ma mua o ka noi synthesis mua ma mua o ka loaʻa ʻole o ka hailona.

Ma kahi e nalowale ai ka hana hoʻomohala peptide i ka manawa: hoʻohuihui, ka hoomaemae ana, a i ʻole ka hoʻokuʻu analytical

Hoʻohuihui, ka hoomaemae ana, hiki i ka analytics a me ka hoʻonohonoho ʻana ke kaupalena i kahi papahana peptide. E ʻike i ke ala koʻikoʻi mai ke ala maoli a me nā moʻolelo handoff; ʻAʻole hiki i kahi hoʻolaha kahua CHO a i ʻole kahi ʻōlelo CDMO ke hoʻonohonoho i kēia mau bottlenecks ma nā peptides āpau.

SPPS maʻemaʻe maʻemaʻe a me nā pae hoʻihoʻi Holo ka maemae maʻemaʻe 60 i 85 pakeneka no nā peptides laina a me ka hoʻihoʻi 50 i 80 pākēneka, e hāʻule ana i 30 i 50 pākēneka no nā huahana paʻakikī. SPPS maʻemaʻe maʻemaʻe a me nā pae hoʻihoʻi. ʻikepili lollipop: Maʻemaʻe maʻemaʻe, laina laina 60; Maʻemaʻe maʻemaʻe, laina kiʻekiʻe 85; Hoʻihoʻi hou, maʻamau 50; Hoʻihoʻi hou, kūlana kiʻekiʻe 80; Hoʻihoʻi hou, paʻakikī 30; Hoʻihoʻi hou, kiʻekiʻe paʻakikī 50.Source: Nā ʻano hana peptide synthesis SPPS pālākiō pāʻoihana . SPPS maʻemaʻe maʻemaʻe a me nā pae hoʻihoʻi Maʻemaʻe maʻemaʻe,laina laina 60 Maʻemaʻe maʻemaʻe,laina kiʻekiʻe 85 Hoʻihoʻi hou,maʻamau 50 Hoʻihoʻi hou,kūlana kiʻekiʻe 80 Hoʻihoʻi hou,paʻakikī 30 Hoʻihoʻi hou,kiʻekiʻe paʻakikī 50 Puna: Nā ʻano hana peptide synthesis SPPS pālākiō pāʻoihana

ʻO ka moʻolelo haumia pili e pili ana i ke kaʻina, kemika a me ka hoomaemae. Mai kuhi i ka helu haumia paʻa a i ʻole ke ao holoʻokoʻa 0.10%/0.5% koi mai kahi ʻōlelo CDMO. Ua haʻalele ka FDA i kāna 2021 alakaʻi ANDA synthetic-peptide maʻamau i Iulai 2026; e ʻimi i nā ʻōlelo aʻoaʻo kikoʻī huahana o kēia manawa.

Ua ʻoi aku ka wikiwiki o ka Synthesis ponoʻī, ka mea e hoʻoneʻe i ka bottleneck i lalo. Hōʻike ʻia kahi haʻawina i nānā ʻia e nā hoa i ka holoi ʻole ʻana i nā manawa pōʻai SPPS ma kahi o 3.5 mau minuke no ka ʻakika amino ma ke kaʻina hoʻohālike a ma kahi o 7.3 minuke no ka waikawa amino no ka 86-mer a me ka 89-mer, me a hiki i 95% hōʻemi ʻōpala holoʻokoʻa a 28.4 L o ka ʻōpala no a 25 mmol liraglutide synthesis kū'ē 139.7 L no ka holo holoi holoi (ʻO nā manawa pōʻai SPPS holoi ʻole a me ka hōʻemi ʻana i ka solvent, 2023-12-09). Hoʻopuka koke ka synthesis i nā mea ʻeleʻele, a ʻo ka ʻāpana ʻōpala e hoʻomaʻemaʻe i ka hoʻomaʻemaʻe a me ka hoʻāʻo hoʻokuʻu analytical. Vip Peptide

He aha ka mea e laka ʻia ma mua o ke kau ʻana i ke kauoha peptide maʻamau

ʻEhā mau mea e hoʻoponopono ʻia ma mua o ke kauoha peptide maʻamau mua, a ʻo kēlā me kēia mea he hoʻoholo kikoʻī ma mua o ka hoʻoholo kūʻai. ʻO ka mua, ʻo ia ke kaʻina pahuhopu me kāna loiloi paʻakikī, no ka mea, ua hoʻoholo nā mea wānana ma luna inā pono ke ala i ka pale iwi kuamoʻo. ʻO ka lua ka ʻano paʻakai a me ka counterion, no ka mea, he hapa maoli ka nuipa counterion o ka mea: Ua hiki i ka maʻiʻo TFA a hiki i 35% o ka huina kaumaha ma mua o ka hoololi ana, kūʻē ma kahi kokoke 25% manaʻo stoichiometrically (ʻO ke aʻo ʻana i ka peptide TFA counterion, 2025).

ʻO ke kolu ke kumu maʻemaʻe. ʻO kahi kiʻi maʻemaʻe chromatographic a me kahi kiʻi ʻikepili peptide net he ana ʻokoʻa, a ʻo ka ʻōlelo kikoʻī hoʻokuʻu e ʻōlelo i ka mea e hoʻokele ai. ʻO ka hā o ka pūʻolo analytical e hele pū me kēlā me kēia ʻāpana, no ka mea, ua wehewehe ʻia ka hoʻāʻo hoʻokuʻu ʻana e nā ʻano a ka papahana i manaʻo ai e hoʻokele.

Ua helu ʻia kēlā mau ʻano ma USP <1503> Nā ʻano maikaʻi o nā mea lāʻau peptide Synthetic, e papa inoa ana i ka ʻike e ka HPLC coelution, MS, ka nānā ʻana i ka ʻakika amino, MS-MS, NMR, ka palapala peptide a me ka chirality, ka hoʻāʻo ʻana e HPLC e kūʻē i kahi maʻamau kuhikuhi, peptide i loko o ka nānā ʻana i ka waikawa amino, ka hoʻoholo ʻana o ka nitrogen a i ʻole ka nui NMR, a me na haumia (USP <1503> ʻano maikaʻi, luna 2021-08-01; kūhelu i kēia manawa 2025-02-12). ʻO ka laka ʻana i ka papa inoa ʻano ma mua o ke kauoha mua ka mea e hoʻohālikelike ai ka hailona mua me ka ʻumi.

He aha nā moʻolelo e pono ai ma mua o ka piʻi ʻana, a me nā mea e pono ai kēlā me kēia pā

Scale-up records are a data-integrity question before they are a manufacturing question. The audit-trail requirement is explicit: use of secure, hana kamepiula, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records, with record changes not obscuring previously recorded information and audit trail documentation retained at least as long as the subject records (21 CFR 11.10(e) audit trail requirements). The same section requires system validation, accurate and complete copies in human-readable and electronic form, mālama moʻolelo no ka manawa mālama, access limited to authorized individuals, operational system checks and authority checks (21 CFR 11.10(e) audit trail requirements).

The field-level expectation comes from the data-integrity definitions: ALCOA means attributable, hiki ke heluhelu, hoʻokahi manawa, kumu a pololei, and ALCOA-plus adds complete, kūlike, hoʻomanawanui a loaʻa, me ka ʻokoʻa ʻole o nā manaʻo me ka nānā ʻole i ka acronym i hoʻohana ʻia (MHRA GxP alakaʻi pono ʻikepili (PDF), 2018). Hoʻopili ʻia i kahi moʻolelo peptide lot, ʻo ia hoʻi kēlā me kēia chromatogram, lawe ʻia nā ʻano kikoʻī nui a me ke ana counterion nāna i holo, i ka manawa, ma ka mea kani, a ma kahi ʻano hiki ʻole ke kākau ʻia.

Paʻa palapala a me ke ʻano kūpono no ka hoʻohana ʻana a me ke kahua. ʻAʻole wehewehe ʻokoʻa nā kūlana hoʻopaʻa inoa ICH maʻamau, helu pūʻulu a i ʻole ka lōʻihi o ke aʻo ʻana no kahi waena noiʻi. E hoʻopili i kēlā me kēia hopena i ka hailona, protocol maoli a me ka ʻae ʻana.

Pehea e haʻi ai i kahi peptide i hoʻoholo ʻia mai kahi ʻāpana i pau

ʻelua kolamu e hoʻohālikelike ana i kahi waena mākaukau hoʻoholo me ka hailona hoʻopau ma waena o ka maʻemaʻe, ʻike ʻike, maʻiʻo, kūpaʻa a

ʻO ka mea waena mākaukau hoʻoholo e pane i hoʻokahi nīnau; he hailona pau i pane ia lakou a pau. ʻO ka ʻokoʻa ka pūʻulu o nā ʻano i hoʻāʻo ʻia i ka mea, ʻaʻole ka helu maʻemaʻe ma ka palapala hōʻoia.

Lawe ʻia kahi waena hoʻoholo hoʻoholo i ka maʻemaʻe chromatographic, he hōʻoia ʻike a lawa ka ʻike haumia e hoʻoholo ai inā e hoʻomau. He pā haʻahaʻa kēlā ma mua o ka hoʻokuʻu ʻana. Hāʻawi ka hailona paʻa i ka hoʻonohonoho pono piha: ʻike ma o nā ʻenehana orthogonal, hōʻike kūʻē i kahi maʻamau kuhikuhi, Synthesis Of Polypeptide Wholesale maʻiʻo peptide, a me kahi moʻolelo haumia i hōʻike ʻia a ʻike ʻole ʻia, ʻo ia ka ʻōnaehana USP <1503> hoʻonohonoho (USP <1503> ʻano maikaʻi).

ʻO nā hopena hoʻololi kū'ē e pili ana i ka peptide, kaʻina hana a me nā palena ʻike. ʻAʻole ʻokoʻa kahi haʻawina hou i ka hoʻohālikelike ikaika i ka wā i hoʻohana ʻia ai nā ʻano hana like ʻole a me nā ʻano analytical. E hōʻoia i ke koena TFA ma ka hailona i manaʻo ʻia.

Nīnau pinepine

ʻO ka hoʻohālikelike gene-to-lead-clone kahi kūlike kūpono no nā peptides?

ʻAʻole, a he mea pono ke hoohewahewa ia mea. ʻAʻohe mea i loko o ka moʻolelo i paʻi ʻia e pili ana i ka ʻōnaehana hōʻike GS i ka hui kaulahao paʻa, hoʻololi kūʻē a i ʻole ka wehe ʻana i ka TFA. ʻOi aku ka haiki a ʻoi aku ka pono o ka mea e lawe ai: ka maʻa o ka hoʻoneʻe ʻana i kahi kaohi i lalo i uka a me ka holoi ʻana i kahi lima, ʻaʻole ka biology o kekahi kahua hoʻokahi. Peptide Kuʻuna

Hiki ke hilinaʻi ʻia nā helu o Lonza inā ua kapa ʻia kekahi mau ʻikepili kākoʻo "ʻaʻole i hōʻike ʻia"?

E mālama iā lākou e like me ka mea kūʻai aku i hōʻike ʻia ma mua o ka hōʻoia kūʻokoʻa. Hoʻopili ʻia nā helu titre a me ka pool-stability ma waena o nā mea pono a Lonza, no laila ke kākoʻo nei lākou kekahi i kekahi me ka ʻole o ka hōʻike ʻokoʻa, a he ʻoihana loiloi o nā ʻōnaehana koho CHO hae i ka ʻāpana o kēlā pūʻulu helu ma ke ʻano he "ʻikepili ʻaʻole i hōʻike ʻia". Pono ke kuhikuhi; ʻaʻole hiki ke hoʻopaʻa ʻia ka pololei.

ʻO ka hoʻomaʻemaʻe wale nō ka lawelawe o lalo?

ʻAʻole ʻōlelo ka kalena. Holoi, Hiki i nā ʻano epimerised a oxidised ke noho kokoke i ka pahuhopu i ka nui a me ka hydrophobicity i hana maʻamau ka co-elution., a hiki i ke kaulahao koena 30 ke kiola 50 i 100 haumia moho. ʻO ka hōʻike bioprocess ma kahi e kū ai nā hoʻoholo kau i ka bottleneck i ka hoʻoholo analytical ma mua o ke kolamu, ʻO ia ke kumu e mālama ai i ka hoʻomaʻemaʻe ʻana ma ke ʻano he lawelawe āu e kūʻai ai ma ka hope misreads kahi e hele ai ka manawa.

Hiki i kahi hui me kahi kaʻina laka ke hoʻōla me ka ʻole e hoʻomaka hou?

ʻAe maʻamau, a noho ka hoʻoponopono i ka hoʻolālā synthesis ma mua o ke kaʻina ponoʻī. A ʻO ka nānā ʻana o nā hoa o ka hydrophobic peptide synthesis wehewehe i ka hoʻokomo ʻana i ka pale iwi kuamoʻo ma mua o ka hoʻomaka ʻana o ka hōʻuluʻulu ʻana a laila i kēlā me kēia koena ʻeono, ka mea e kaohi ai i ke kiko paakiki me ka hoopa ole i ke kauoha. Noho ka peptide e like me ka hoʻolālā; hoʻololi ke ala a me ke ʻano hoʻomaʻemaʻe. ʻO ia ke kumu kūpono e pono ai ka hoʻolālā ʻana o ka peptide sequence e hoʻopaʻa i kahi hana hana i heluhelu ʻia ma ka ʻaoʻao o ke kaʻina, no laila, loaʻa kahi kauoha paʻa i kahi e hele ai.

Ka hopena

ʻO ka haʻawina hiki ke hoʻololi ʻia mai GS-ORI-GO ʻaʻole ia he mea hoʻolaha a i ʻole kahi māka koho. ʻO ia ka hoʻoholo mua ʻana o nā polokalamu wikiwiki i nā mea paʻakikī: ʻo ia nā waiwai kaʻina e hoʻokau i ka paʻakikī synthesis, ʻo ia ka paʻakai a me ka counterion e lawe ai ka papahana, e pili ana i ka palapala hōʻoia e hōʻike, a he aha nā moʻolelo e loaʻa ma mua o ka piʻi ʻana. Hōʻike nā helu ponoʻī o Lonza i ka mea e kūʻai ai ka hoʻohui mua ma ka ʻaoʻao biologics, me nā titers kepau-clone kiʻekiʻe ma mua o 11 mākaukau g/L a me IND i loko o ʻeono mahina ma lalo o ka footnote kūpono (ʻO Lonza 3 Iune 2026 aʻoaʻo media; ʻO Lonza ma ka hoʻolālā vector hōʻike mua). ʻO ka ʻaoʻao peptide kahi papa inoa i hoʻopaʻa ʻia a me kahi ala i hoʻopaʻa ʻia ma mua o ke kauoha mua, ʻaʻole he reactor ʻoi aku ka wikiwiki.

ʻO ka hana aʻe he loiloi papa inoa: hōʻoia i ka loiloi paʻakikī, ke ano paakai, ua hoʻoholo ʻia ke kumu maʻemaʻe a me ka pūʻolo analytical, then confirm the lot record can produce an audit trail that satisfies 21 CFR 11.10(e) before the first scale-up batch is scheduled.


Mea hoʻopuka: MOL Changes. Hoʻohou 15 ʻOkakopa 2026. Hoʻopili kēia ʻatikala i nā kumu lehulehu i ʻōlelo ʻia a hāʻawi i kahi hoʻolālā hoʻolālā. ʻAʻole ia e hōʻike i kahi loiloi hoʻolako kūʻokoʻa a i ʻole kahi noiʻi hoʻokolohua MOL Changes kumu.

Hōʻike kālepa: Hāʻawi ʻo MOL Changes i nā lawelawe peptide a loaʻa iā ia kahi hoihoi pāʻoihana i kēia kumuhana. Pono e hoʻopaʻa ʻia ka mana o ka papahana a me ka laulā analytical e kūʻē i ka hoʻohana i manaʻo ʻia a me kahi kikoʻī i kākau ʻia.

Miao He

Miao He

ʻepekema noiʻi ma nā ʻōnaehana hoʻouna Kaʻike kumu: Hāʻawi peptide waha, lipid nanoparticle (LNP) hoʻopili ʻana, nā peptides komo i loko o ke kelepona (CPPs), a me nā hoʻopuka hoʻokuʻu mau.

Pilikino: ʻO nā luʻi nui i ka hoʻomohala ʻana i nā lāʻau peptide aia i loko o ko lākou mau hapalua ola pōkole a paʻakikī me ka hoʻokele waha, a ʻo Miao ʻO ia kekahi loea alakaʻi i ka hoʻoponopono ʻana i kēia mau pilikia. Loaʻa iā ia ka ʻike nui ma ke kahua o nā ʻōnaehana lawe peptide. Ke hoʻomau nei ʻo ia i ka hoʻomohala ʻana i nā mea hoʻonui permeation novel a me nā nanospheres e hoʻomaikaʻi nui i ka bioavailability o peptides..

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana